#Japan #Tokyo #CSL Behring #Edward Wright

CSL Behring Welcomes Edward Wright as New CEO in Japan

CSL Behring recently announced the appointment of Edward Wright as the new President and CEO of its Japan operations, effective from October 19, 2026. With over two decades of rich experience across the pharmaceutical, government, and finance sectors, Wright is poised to lead the company in its mission to deliver life-saving biologics to patients worldwide.

Wright's extensive skill set encompasses commercial strategy, business development, market access, and governmental affairs, making him a well-rounded leader in the healthcare landscape. His deep understanding of the Japanese medical system, paired with his insights into policy and regulatory environments, will serve as a significant asset for CSL Behring Japan. Previously, he held the position of General Manager and CEO at Clinigen Group plc, where he also managed operations in South Korea, demonstrating his regional expertise.

Before his tenure at Clinigen, Wright had significant roles at Bayer and Novartis, focusing on specialty care and strategic partnerships. Moreover, he began his career as a science officer at the British Embassy in Japan, where he gained invaluable insights into the life sciences sector. His early experiences and professional journey provide him with a unique perspective on the industry's nuances.

Academically, Wright holds a Bachelor of Arts degree in Chemistry from the prestigious University of Oxford. He further advanced his education with a PhD in Chemistry from the University of Cambridge, an MBA from INSEAD, and a Bachelor of Science degree in International Relations from the London School of Economics. This combination of scientific expertise and business acumen positions him as a knowledgeable leader in the biopharmaceutical industry.

Jean-Marc Morange, Senior Vice President and General Manager for Asia Pacific, expressed confidence in Wright's capabilities in steering the company towards growth. He stated, "Edward's profound insights into Japan's healthcare environment and his extensive experience across science, healthcare policy, and business management are expected to be instrumental in driving CSL Behring Japan's growth. Under his leadership, we aim to continue delivering sustainable value to patients facing rare and difficult-to-treat diseases, while further contributing to the development of Japan's healthcare landscape."

About CSL Behring

CSL Behring specializes in innovative biologics for the treatment of severe and rare diseases. Dedicated to serving patients globally, the company focuses on various domains such as immunology, rare diseases, hereditary angioedema (HAE), hemophilia, and emergency medicine. For more details, you can visit their site at CSL Behring Japan.

About CSL Limited

Founded in 1916, CSL Limited (ASX: CSL, USOTC: CSLLY) is a global biotechnology company with a broad portfolio of life-saving medicines, including therapies for hemophilia, immune deficiencies, and influenza vaccines. Their commitment to employing cutting-edge technology to save lives has driven their operations since inception. With 29,000 employees across three business segments—CSL Behring, CSL Seqirus, and CSL Vifor—they contribute to the well-being of patients in over 100 countries. For insights into the future of biotechnology, visit CSL Behring Vita and for more company details, go to CSL Limited.